NIKKEI 225
23,494.34-22.25(-0.09%)HANG SENG
24,918.78+132.68(+0.54%)CRUDE OIL
38.57-1.28(-3.21%)
Arrowhead Pharmaceuticals, Inc. (ARWR)
| Previous close | 58.88 |
| Open | 58.25 |
| Bid | 58.77 x 1200 |
| Ask | 58.86 x 800 |
| Day's range | 57.97 - 60.49 |
| 52-week range | 19.51 - 73.72 |
| Volume | 1,171,853 |
| Avg. volume | 1,511,715 |
| Market cap | 6.002B |
| Beta (5Y monthly) | 1.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings date | 23 Nov 2020 - 27 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.64 |
- Motley Fool
Why Arrowhead Pharmaceuticals Stock Jumped Today
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) released an update regarding one of its pipeline candidates, and the update bodes well for Arrowhead and its shareholders. On Wednesday evening, Vertex announced it would discontinue the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung or liver disease.
- Simply Wall St.
The Consensus EPS Estimates For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Just Fell Dramatically
The analysts covering Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) delivered a dose of negativity to shareholders...
- Business Wire
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda and Arrowhead announced a collaboration and licensing agreement to develop ARO-AAT, a Ph. 2 investigational RNAi therapy to treat AATLD.
